Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

Subscribe To Our Latest Investor News

News Highlights

Combination of copanlisib and rituximab significantly increases progression-free survival in patients with relapsed indolent non-Hodgkin's Lymphoma

Bayer to present new clinical data at AACR Annual Meeting 2021

Not intended for U.S. and UK Media

Bayer receives approval for Vitrakvi™ in Japan

Elections at the Annual Stockholders' Meeting on April 27, 2021

Discover Bayer’s Latest Ad Hoc Releases

Explore All

21 - 30of about 613 News

21 - 30of about 613 News

December 02, 2020

Bayer establishes Cell and Gene Therapy Platform to accelerate pharmaceutical innovation

December 01, 2020

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL

Bayer announces placement of Elanco shares for gross proceeds of 1.6 billion U.S. dollars at completion

November 17, 2020

Not intended for U.S. and UK Media - Late-Breaking Data from subgroup analysis of Phase III FIDELIO-DKD study presented at the American Heart Association (AHA) Scientific Sessions 2020

Finerenone showed consistent benefits on cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes with or without history of cardiovascular disease

November 13, 2020

Not intended for U.S. and UK Media

Positive CHMP opinion for extension of rivaroxaban marketing authorization to treat venous thromboembolism (VTE) in children

November 12, 2020

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

November 09, 2020

Not intended for U.S. and UK Media

Bayer submits marketing authorization applications for finerenone in the U.S. and the EU for patients with chronic kidney disease and type 2 diabetes

November 03, 2020

Bayer:

Challenging third quarter – Group outlook confirmed

October 27, 2020

The U.S. EPA announces new 5-year registration for XtendiMax® herbicide, Bayer’s low-volatility dicamba product

October 27, 2020

Bayer appoints Dr. Christian Rommel as new Head of Pharmaceuticals Research and Development

October 26, 2020

Bayer acquires Asklepios BioPharmaceutical to broaden innovation base in cell and gene therapy